DiaMedica Therapeutics In... (DMAC)
Company Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases.
The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke.
It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases.
The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016.
DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
| Country | United States |
| IPO Date | Aug 3, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Dietrich John Pauls MBA |
Contact Details
Address: Two Carlson Parkway Minneapolis, Minnesota United States | |
| Website | https://www.diamedica.com |
Stock Details
| Ticker Symbol | DMAC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001401040 |
| CUSIP Number | 25253X207 |
| ISIN Number | CA25253X2077 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dietrich John Pauls MBA | President, Chief Executive Officer & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 08, 2025 | 4 | Filing |
| Mar 28, 2025 | ARS | Filing |
| Mar 28, 2025 | DEFA14A | Filing |
| Mar 28, 2025 | DEF 14A | Filing |
| Mar 17, 2025 | 10-K | Annual Report |
| Mar 17, 2025 | 8-K | Current Report |
| Mar 06, 2025 | 8-K | Current Report |
| Feb 24, 2025 | 4 | Filing |
| Feb 24, 2025 | 3 | Filing |
| Feb 24, 2025 | 8-K | Current Report |